stockportfolio.pro
Protagonist Therapeutics, Inc. Free Cash Flow 2014–2025
Protagonist Therapeutics, Inc. (PTGX) annual free cash flow by fiscal year, computed from SEC filings.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $56.08M | -69.3% |
| FY 2024 | $182.80M | +358.0% |
| FY 2023 | $-70.84M | +35.0% |
| FY 2022 | $-108.93M | +0.0% |
| FY 2021 | $-108.97M | -49.4% |
| FY 2020 | $-72.95M | -71.7% |
| FY 2019 | $-42.49M | +15.7% |
| FY 2018 | $-50.43M | -1673.1% |
| FY 2017 | $3.21M | +110.6% |
| FY 2016 | $-30.32M | -105.1% |
| FY 2015 | $-14.78M | -83.8% |
| FY 2014 | $-8.04M | — |
Source: Protagonist Therapeutics, Inc. SEC filings — cash flow statement (10-K). Refreshed nightly.
See the full picture for Protagonist Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeProtagonist Therapeutics, Inc. — frequently asked questions
What is Protagonist Therapeutics, Inc.'s free cash flow?
Protagonist Therapeutics, Inc. (PTGX) reported free cash flow of $56.08M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Protagonist Therapeutics, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.